Clinical trials: Myocardial Ischaemia
Coronary Artery Disease Obliterative, Chronic Total Occlusion (CTO)
A Prospective, Non-Randomized Pivotal Clinical Investigation to Demonstrate the Safety and Performance of the TrueCross Single-Use Microcatheter
The trial is a pivotal clinical investigation, which is a prospective, non-randomized pivotal clinical investigation to demonstrate the safety and performance of the TrueCross Single-use Microcatheter.
- Trial name
- NCT06030271
- Testing
- Microcatheter
- Where
- 7 sites in Georgia, Greece and 1 more
- Volunteers
- 60 people
- Sponsor
- Insight Lifetech Co., Ltd.
Myocardial Infarction
Safety Study of Allogeneic Mesenchymal Precursor Cells (MPCs) in Subjects With Recent Acute Myocardial Infarction
Primary Objective The primary objective of this study is to evaluate the safety and feasibility of transendocardial injection using the Cordis Biosense NogaStarTM Mapping Catheter with the Biosense MyostarTM Left Ventricular…
- Trial name
- NCT00555828
- Testing
- Allogeneic Mesenchymal Precursor Cells (MPCs), Standard-of-care treatment with NOGA® mapping and staged injections.
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Angioblast Systems
Coronary Artery Disease
GLOBAL Clinical Study
The GLOBAL study is an international multi-center, prospective study designed to enroll up to 10,000 consecutive eligible subjects who are clinically referred for coronary CT angiography for assessment of suspected coronary…
- Trial name
- GLOBAL (NCT01738828)
- Where
- 48 sites in United States, Australia and 7 more
- Volunteers
- 10,000 people
- Sponsor
- Global Genomics Group, LLC
Hypercholesteremia, Coronary Artery Disease
Lipitor Phase 4 Clinical Trial in Hypercholesteremia Patients With Yellow Coronary Plaque
To evaluate the efficacy of intensive lipid-lowering therapy with Lipitor on the changes of characteristics of yellow coronary plaque in subjects with hypercholesteremia accompanying coronary artery disease
- Trial name
- NCT00408382
- Testing
- atorvastatin, Lipitor
- Where
- 2 sites in Japan
- Volunteers
- 50 people
- Sponsor
- Astellas Pharma Inc
Coronary Artery Disease
Pilot Study of the Fantom Bioresorbable Scaffold (FANTOM I)
The FANTOM I pilot study is intended to assess safety of the Fantom Bioresorbable Coronary Scaffold in native coronary arteries.
- Trial name
- FANTOM I (NCT02512003)
- Testing
- Fantom Scaffold
- Where
- 2 sites in Brazil, Poland
- Volunteers
- 7 people
- Sponsor
- REVA Medical, Inc.
Myocardial Infarction
Clinical Performance Evaluation of AQT90 FLEX TnI and TnT
The AQT90 FLEX Troponin I (TnI) and Troponin T (TnT) Tests are in vitro diagnostic assays intended as an aid in the diagnosis of myocardial infarction (MI) in point-of-care and laboratory settings.
- Trial name
- NCT02624024
- Where
- 8 sites in United States
- Volunteers
- 1,743 people
- Sponsor
- Radiometer Medical ApS
Coronary Artery Disease
Comparisons of Morphological Measurement Between Coronary Computed Tomography and Optical Coherence Tomography
The objective of this study is to evaluate the precision of semi-automated lumen boundary identification from coronary computed tomography angiography (cCTA) by current version of HeartFlow software and the impact on fractional…
- Trial name
- NCT03021382
- Testing
- data collection, non-intervention
- Where
- Japan
- Volunteers
- 72 people
- Sponsor
- Kobe University
In-Stent Restenosis
PERVIDEO I Registry, The Lutonix Paclitaxel-Coated Balloon Catheter for the Treatment of Coronary In-Stent Restenosis
The study will enroll patients with angiographic evidence of in-stent restenosis of a previously placed bare-metal stent. Subjects will be treated with a Lutonix Catheter.
- Trial name
- PERVIDEO I (NCT00916279)
- Testing
- Lutonix Paclitaxel-Coated Balloon
- Where
- 8 sites in Belgium, Germany and 1 more
- Volunteers
- 41 people
- Sponsor
- C. R. Bard
Coronary Artery Disease, Autosomal Dominant, 1
PROTECT Continued Access Post Marketing Surveillance Trial
In order to expand safety information in patients treated with the Endeavor Drug Eluting Stent System, or next generation model, a Continued Access (CA) study is added to the PROTECT Trial.
- Trial name
- PROTECT-CA (NCT00846846)
- Testing
- Endeavor® Zotarolimus Eluting Coronary Stent System
- Where
- United States
- Volunteers
- 1,018 people
- Sponsor
- Medtronic Vascular
Acute Coronary Syndrome
MT1002 Phase II Study in ACS Patients With PCI
This is an open-label, sequential-dose escalation/de-escalation trial testing 3 dose levels of MT1002 in patients undergoing PCI due to ACS with NSTEMI.
- Trial name
- NCT04723186
- Testing
- MT1002 for Injection
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Coronary Artery Disease, Coronary Disease
Post-Market CorPath Registry on the CorPath 200 System in Percutaneous Coronary Interventions
To collect data on the routine patterns of use, safety and effectiveness, including the clinical and technical performance of the CorPath 200 System, in the delivery and manipulation of coronary guidewires and stent/balloon…
- Conditions
- Coronary Artery Disease, Coronary Disease, Myocardial Ischemia, Heart Diseases
- Trial name
- PRECISION (NCT01917682)
- Testing
- CorPath-assisted Percutaneous Coronary Intervention
- Where
- 16 sites in United States, Israel
- Volunteers
- 754 people
- Sponsor
- Siemens Healthineers Endovascular Robotics, Inc.
Prevention & Control
Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease
The primary objectives of this study are: To determine whether rivaroxaban 2.5 mg twice daily (bid) + aspirin 100 mg once daily (od) compared with aspirin 100 mg od reduces the risk of a composite of myocardial infarction…
- Trial name
- COMPASS (NCT01776424)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Aspirin, Pantoprazole
- Where
- 565 sites in United States, Argentina and 31 more
- Volunteers
- 27,395 people
- Sponsor
- Bayer
Coronary Artery Disease, Cardiovascular Disease
Evaluation of the CAD-det System, a Novel Non-Invasive Acoustic Diagnostic for the Diagnosis of Coronary Artery Disease
The primary purpose of this multi-center study is to collect and study the acoustic and electrical signals created by the heart during the cardiac cycle as a result of stenosis or plaque associated with coronary artery disease…
- Trial name
- CAD-det (NCT03914079)
- Where
- 3 sites in Canada
- Volunteers
- 2,000 people
- Sponsor
- AusculSciences Canada Inc.
Coronary Artery Disease
The PLATFORM Study: Prospective LongitudinAl Trial of FFRct: Outcome and Resource IMpacts)
The objective of the PLATFORM Study is to compare clinical outcomes, resource utilization, and quality of life (QOL) of FFRCT-guided evaluation versus standard practice evaluation in patients with suspected CAD in order to…
- Trial name
- PLATFORM (NCT01943903)
- Where
- 15 sites in United States, Austria and 6 more
- Volunteers
- 584 people
- Sponsor
- HeartFlow, Inc.
Coronary Artery Disease
Clinical Trial of Cilostazol Eluting Stent System (CES-1) in De Novo Coronary Artery Lesions
The purpose of the this trial is to evaluate the clinical safety and efficacy of Cilostazol eluting stent system (CES-1) for the treatment of single de novo lesions in native coronary arteries.
- Trial name
- NCT03189641
- Testing
- Cilostazol eluting stent system (CES-1)
- Where
- 6 sites in Japan
- Volunteers
- 30 people
- Sponsor
- JIMRO Co., Ltd.
Diabetes Mellitus Type 2, Cardiovascular Diseases
PRimary IndividualiZed Evaluation of Cardiovascular Events in Patients With Diabetes Mellitus Using hemoTAG
To evaluate the proportion of diabetic mellitus patients with CV events as measured by HEMOTAG.
- Conditions
- Diabetes Mellitus Type 2, Cardiovascular Diseases, Coronary Artery Disease, Cerebrovascular Disease
- Trial name
- PRIZETAG (NCT06567795)
- Testing
- Hemotag
- Where
- United States
- Volunteers
- 189 people
- Sponsor
- Aventusoft, LLC.
Coronary Artery Disease
Impact of Coronary Artery Stenting on Quantitative Myocardial Blood Flow and Health Status
We propose to perform PET MPI studies in patients before and after stenting to evaluate changes (or lack thereof) in MBFR and how that is associated with changes (or lack thereof) in symptoms, functional status and quality of…
- Trial name
- NCT04475094
- Testing
- Rubidium-82, Seattle Angina Questionnaire-7, Rose Dyspnea Scale
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Cardiovascular Imaging Technologies
Chronic Total Occlusion, Ischemic Heart Disease
Chronic Total Occlusion Percutaneous Coronary Intervention Study
The objective of this study is to evaluate angiographic confirmation of placement of any guidewire beyond the CTO, in the true vessel lumen, in patients undergoing CTO percutaneous coronary intervention (PCI) in which at least…
- Conditions
- Chronic Total Occlusion, Ischemic Heart Disease, Chronic Total Occlusion of Coronary Artery
- Trial name
- CTO-PCI (NCT03988166)
- Testing
- Chronic Total Occlusion Revascularization, GuideLiner® V3 catheter, TrapLiner® catheter, Turnpike® catheter
- Where
- 13 sites in United States
- Volunteers
- 150 people
- Sponsor
- Vascular Solutions LLC
Ischemic Cardiomyopathy, Coronary Artery Disease
Stem Cell Implantation in Patients Undergoing CABG
The primary objective of this study is to demonstrate the feasibility and safety of intra-operative, intra-myocardial injection of autologous CD133 positive bone marrow cells at the time of coronary artery bypass graft (CABG)…
- Trial name
- NCT01721902
- Testing
- Autologous CD133+ Bone Marrow Stem Cells, Carrier Solution
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Miltenyi Biotec, Inc.
Coronary Artery Disease, Drug Eluting Balloon
Stents Versus PAclitaxel Coated Balloons for Revascularization of CompleX and Small Coronary Vessels (SPARX) Trial
The main objective of the SPARX trial is to compare paclitaxel-coated balloons to with contemporary DES in complex and small coronary artery lesions in patients with NSTEACS or CCS; the co-primary objective is to compare two…
- Conditions
- Coronary Artery Disease, Drug Eluting Balloon, Drug Eluting Stent
- Trial name
- SPARX RCT (NCT07397845)
- Testing
- Protégé and Protégé NC, Agent, Drug Eluting Stent
- Where
- Switzerland
- Volunteers
- 1,380 people
- Sponsor
- Translumina GmbH
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.